PARTNERSHIP OPPORTUNITIES
As M&A industry trends and patient demand continues to favor further development into obesity and weight loss drugs, big pharma and innovative biotechs are actively investing and diversifying their pipelines in this area.
Obesity drug developers need human-relevant models, sophisticated screening, advanced biomarkers, and clinical CROs to streamline clinical trial management in a disease with many co-morbidities. Your support has the potential to catalyze revolutionary advancements in the field.
Partner of the 2nd Obesity and Weight Loss Summit were present at the 3-day event with preclinical, clinical and translational obesity experts. This summit offered a unique opportunity to network with industry giants and pioneers, propelling your solutions to the top of their list and making accessible, safe and sustainable obesity therapeutics a reality.
2024 Partners
What Experts Needed From You
Human-relevant models which can predict cardiovascular safety and tolerability
CROs which can account for the significant heterogeneity of obesity
Sophisticated screening to stratify patients
Advanced biomarkers
Top Reasons to Partner
Thought Leadership: Present a compelling talk to shape the perspectives of preclinical, translational, and clinical decision-makers dedicated to discovering promising new compounds and ensuring success in the clinical setting
Brand Exposure: Position your brand prominently and showcase cutting-edge solutions to an exclusive audience actively seeking new solutions to optimize drug development inefficiencies
Bespoke Networking Opportunities: Establish valuable connections with decision-makers and key opinion leaders, opening doors to potential collaborative partnerships and business prospects
Who Was in Attendance in 2024?
Register Interest
Ellie Bilko
Program Director
Hanson Wade
sponsor@hansonwade.com